MedinCell S.A. (EPA:MEDCL)
22.56
-0.52 (-2.25%)
At close: Jan 30, 2026
MedinCell Revenue
MedinCell had revenue of 14.15M EUR in the half year ending September 30, 2025, with 72.95% growth. This brings the company's revenue in the last twelve months to 32.44M, up 145.75% year-over-year. In the fiscal year ending March 31, 2025, MedinCell had annual revenue of 27.73M with 132.12% growth.
Revenue (ttm)
32.44M
Revenue Growth
+145.75%
P/S Ratio
23.02
Revenue / Employee
223.72K
Employees
145
Market Cap
746.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.73M | 15.78M | 132.12% |
| Mar 31, 2024 | 11.95M | -1.71M | -12.52% |
| Mar 31, 2023 | 13.66M | 5.32M | 63.77% |
| Mar 31, 2022 | 8.34M | 152.00K | 1.86% |
| Mar 31, 2021 | 8.19M | 2.19M | 36.43% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 179.91M |
| Cellectis | 70.36M |
| Genfit | 45.13M |
| Inventiva | 16.97M |
| Adocia | 12.88M |
| Innate Pharma | 12.64M |
| Nanobiotix | 10.16M |
| Transgene | 7.58M |
MedinCell News
- 4 months ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
- 4 months ago - Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed - Nasdaq
- 1 year ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha